Lineage Cell Therapeutics, Inc. (TLV: LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	27.75	35.44	11.36	55.74	32.59	9.5
Short-Term Investments	4.96	0.05	46.52	2.62	8.98	21.22
Cash & Short-Term Investments	32.71	35.49	57.88	58.36	41.56	30.72
Cash Growth	-20.86%	-38.67%	-0.83%	40.41%	35.31%	-0.08%
Accounts Receivable	0.41	0.75	0.3	50.84	0	0.32
Receivables	0.41	0.75	0.3	50.84	0	23.94
Prepaid Expenses	1.29	2.18	1.83	2.35	2.36	2.86
Restricted Cash	-	-	-	-	0.08	-
Other Current Assets	-	0.02	-	-	-	-
Total Current Assets	34.4	38.44	60	111.55	44	57.52
Property, Plant & Equipment	4.38	4.77	5.67	4.87	5.63	8.18
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	46.54	46.56	46.69	46.82	47.03	48.25
Other Long-Term Assets	0.61	0.58	0.63	0.63	0.62	0.86
Total Assets	96.59	101.02	123.66	174.55	107.95	125.48
Accounts Payable	1.6	2.05	2.39	3.54	2.61	2.43
Accrued Expenses	2.88	4.22	6.22	24.25	3.67	2.8
Short-Term Debt	-	-	-	-	0.52	-
Current Portion of Leases	1.14	0.88	0.95	0.83	0.76	1.22
Current Unearned Revenue	8.25	10.81	9.42	18.12	0.19	0.05
Other Current Liabilities	-	-	-	0.38	0.01	0
Total Current Liabilities	13.86	17.96	18.98	47.12	7.77	6.49
Long-Term Leases	1.61	2.07	2.94	1.97	2.54	3.95
Long-Term Unearned Revenue	16.05	18.69	27.73	32.45	-	0.2
Long-Term Deferred Tax Liabilities	0.27	0.27	2.08	2.08	2.08	3.32
Other Long-Term Liabilities	-	-	0	0.03	0.44	0.28
Total Liabilities	31.8	39	51.73	83.65	12.82	14.23
Common Stock	469.27	451.34	440.28	434.53	393.94	387.06
Retained Earnings	-400.19	-384.86	-363.37	-337.1	-294.08	-273.42
Comprehensive Income & Other	-2.89	-3.07	-3.57	-5.21	-3.67	-0.68
Total Common Equity	66.19	63.42	73.34	92.22	96.2	112.96
Minority Interest	-1.39	-1.4	-1.4	-1.32	-1.07	-1.71
Shareholders' Equity	64.79	62.02	71.94	90.9	95.13	111.25
Total Liabilities & Equity	96.59	101.02	123.66	174.55	107.95	125.48
Total Debt	2.75	2.95	3.9	2.8	3.83	5.17
Net Cash (Debt)	29.96	32.54	53.98	55.56	37.74	25.55
Net Cash Growth	-21.67%	-39.72%	-2.84%	47.22%	47.71%	-10.28%
Net Cash Per Share	0.16	0.19	0.32	0.34	0.25	0.18
Filing Date Shares Outstanding	188.84	188.53	170.15	169.71	161.64	149.81
Total Common Shares Outstanding	188.84	174.99	170.09	169.48	153.1	149.8
Working Capital	20.54	20.48	41.02	64.43	36.23	51.03
Book Value Per Share	0.35	0.36	0.43	0.54	0.63	0.75
Tangible Book Value	8.97	6.19	15.98	34.73	38.5	54.04
Tangible Book Value Per Share	0.05	0.04	0.09	0.20	0.25	0.36
Machinery	3.74	3.61	3.26	3.47	3.63	4.15
Leasehold Improvements	2.26	2.31	2.15	2.54	2.47	2.86

Source: S&P Capital IQ. Standard template. Financial Sources.